|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
153,922,000 |
Market
Cap: |
6.15(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$39.95 - $39.95 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile IVERIC bio is biopharmaceutical company focused on the discovery and development of treatments for retinal diseases with unmet medical needs. Co.'s clinical stage product candidate, Zimura® (avacincaptad pegol), a complement C5 inhibitor. Co. is targeting the following diseases with Zimura: Geographic Atrophy, intermediate age-related macular degeneration, and autosomal recessive Stargardt disease. In addition to Zimura, Co. is developing its preclinical product candidate IC-500, a high temperature requirement A serine peptidase 1 protein inhibitor, for GA and potentially other age-related retinal diseases.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
0 |
0 |
541,223 |
Total Sell Value |
$0 |
$0 |
$0 |
$15,166,753 |
Total People Sold |
0 |
0 |
0 |
4 |
Total Sell Transactions |
0 |
0 |
0 |
28 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Simms Christopher Paul |
SVP, Chief Commercial Officer |
|
2023-01-03 |
4 |
S |
$20.06 |
$47,502 |
D/D |
(2,368) |
32,429 |
|
-87% |
|
Carroll David Francis |
SVP, Chief Financial Officer |
|
2023-01-03 |
4 |
S |
$20.06 |
$72,256 |
D/D |
(3,602) |
68,472 |
|
-87% |
|
Sblendorio Glenn |
Chief Executive Officer |
|
2023-01-03 |
4 |
S |
$20.06 |
$349,987 |
D/D |
(17,447) |
228,191 |
|
-87% |
|
Westby Keith |
SVP, Chief Operating Officer |
|
2023-01-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,750 |
89,834 |
|
- |
|
Simms Christopher Paul |
SVP, Chief Commercial Officer |
|
2023-01-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,250 |
34,797 |
|
- |
|
Carroll David Francis |
SVP, Chief Financial Officer |
|
2023-01-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,750 |
72,074 |
|
- |
|
Dugel Pravin |
President |
|
2023-01-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
12,500 |
148,723 |
|
- |
|
Sblendorio Glenn |
Chief Executive Officer |
|
2023-01-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
31,500 |
245,638 |
|
- |
|
Sblendorio Glenn |
Chief Executive Officer |
|
2022-12-27 |
4 |
GD |
$0.00 |
$0 |
D/D |
30,000 |
214,138 |
|
- |
|
Sblendorio Glenn |
CEO |
|
2022-12-19 |
4 |
S |
$21.51 |
$418,520 |
D/D |
(19,457) |
244,138 |
|
-77% |
|
Westby Keith |
SVP & COO |
|
2022-12-19 |
4 |
S |
$21.51 |
$144,977 |
D/D |
(6,740) |
81,084 |
|
-77% |
|
Carroll David Francis |
CFO |
|
2022-12-19 |
4 |
S |
$21.51 |
$121,983 |
D/D |
(5,671) |
63,324 |
|
-77% |
|
Dugel Pravin |
President |
|
2022-12-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
13,750 |
136,223 |
|
- |
|
Sblendorio Glenn |
CEO |
|
2022-12-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
36,658 |
263,595 |
|
- |
|
Westby Keith |
SVP & COO |
|
2022-12-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
12,500 |
87,824 |
|
- |
|
Carroll David Francis |
CFO |
|
2022-12-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
14,375 |
68,995 |
|
- |
|
Gibney Anthony S |
EVP, Chief Business Officer |
|
2022-12-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
31,000 |
42,791 |
|
- |
|
Westby Keith |
SVP & COO |
|
2022-12-13 |
4 |
S |
$21.73 |
$146,482 |
D/D |
(6,741) |
75,324 |
|
-38% |
|
Carroll David Francis |
CFO |
|
2022-12-13 |
4 |
S |
$21.73 |
$107,172 |
D/D |
(4,932) |
54,620 |
|
-38% |
|
Westby Keith |
SVP & COO |
|
2022-12-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
12,500 |
82,065 |
|
- |
|
Westby Keith |
SVP & COO |
|
2022-12-12 |
4 |
S |
$20.66 |
$112,662 |
D/D |
(5,393) |
69,565 |
|
-49% |
|
Sblendorio Glenn |
CEO |
|
2022-12-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
22,950 |
226,937 |
|
- |
|
Carroll David Francis |
CFO |
|
2022-12-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
12,500 |
59,552 |
|
- |
|
Carroll David Francis |
CFO |
|
2022-12-12 |
4 |
S |
$20.66 |
$82,434 |
D/D |
(3,946) |
47,052 |
|
-49% |
|
Westby Keith |
SVP & COO |
|
2022-12-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,000 |
74,958 |
|
- |
|
459 Records found
|
|
Page 3 of 19 |
|
|